Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 31, 2009

Novartis to Exploit Nuevolution Platform for Drug Discovery

  • Novartis enlisted the help of Danish drug discovery company Nuevolution to identify small molecule leads against specific drug targets. Nuevolution will use its fragment-based drug screening platform called Chemetics®. The company says this technology combines proven wet chemistry and molecular biology to allow the rapid synthesis and selection of ligands from potentially billions of drug-like compounds in a single test tube.  The companies will work together to carry out hit-to-lead optimization.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »